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Pretreatment rate of decay in 
forced vital capacity predicts long-
term response to pirfenidone in 
patients with idiopathic pulmonary 
fibrosis
Davide Biondini1, Elisabetta Balestro1, Donato Lacedonia2, Stefania Cerri3, Rosanna Milaneschi4, 
Fabrizio Luppi3, Elisabetta Cocconcelli1, Erica Bazzan1, Enrico Clini  5, Maria Pia Foschino 
Barbaro2, Dario Gregori1, Manuel G Cosio1,6,  Marina Saetta1 & Paolo Spagnolo1
Pirfenidone reduces functional decline in patients with Idiopathic Pulmonary Fibrosis (IPF). However, 
response to treatment is highly heterogeneous. We sought to evaluate whether response to pirfenidone 
is influenced by the pretreatment rate of forced vital capacity (FVC) decline. Fifty-six IPF patients 
were categorized as rapid (RP) or slow progressors (SP) based on whether their FVC decline in the 
year preceding pirfenidone treatment was > or ≤ 10% predicted. Following pirfenidone treatment 
patients were followed-up every 6 months and up to 24 months. In the entire population, pirfenidone 
reduced significantly FVC decline from 231 to 49 ml/year at 6 months (T6) (p = 0.003) and this effect was 
maintained at the 12-, 18- and 24-month time points (p value for trend n.s.). In RP, the reduction of FVC 
decline was evident at 6 months (36 vs 706 ml/year pretreatment; p = 0.002) and maintained, though 
to a lesser degree, at 12 (106 ml/year), 18 (176 ml/year) and 24 months (162 ml/year; p value for trend 
n.s). Among SP, the reduction in FVC decline was not significant at any of the time points analyzed. 
In conclusion, pirfenidone reduces FVC decline in IPF patients. However, its beneficial effect is more 
pronounced in patients with rapidly progressive disease.
Idiopathic pulmonary fibrosis (IPF), the most common and severe of the idiopathic interstitial pneumonias 
(IIPs), is a chronic and relentlessly progressive disease of unknown origin with a median survival of 3–5 years 
from diagnosis1. While the overall prognosis of IPF is poor, its rate of decline and progression to death is highly 
variable with some patients remaining relatively stable over a prolonged period of time or progressing slowly, and 
others experiencing a rapid decline2,3. The heterogeneous nature of the disease makes it difficult, if at all possible, 
to foresee the clinical trajectory in individual patients. Several risk prediction models have been developed in IPF, 
but their predictive capability is only moderate4–6.
Forced vital capacity (FVC) is a reliable, valid and reproducible measure of disease progression in patients with 
IPF1,7, and change in FVC percentage predicted (FVC% pred.) over time is a well-established predictor of mor-
tality. Indeed, it has been shown that patients who experience a decrease in FVC% pred. greater than 10% over a 
12-month period have a significantly lower 5-year survival compared to patients whose FVC% pred. declines of 
10% or less during the same period of time8. While there is no universally agreed upon definition for these two 
clinical phenotypes, they are commonly referred to as “rapid” and “slow” progressors, respectively. Notably, the 
observation that rapidly progressive and relatively stable/slowly progressive patients with IPF display distinct 
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gene expression9,10 and inflammatory profiles in the lung parenchyma3 supports the notion that the mechanisms 
underlying these distinct clinical phenotypes may also be different.
Pirfenidone, a pyridone derivative with anti-inflammatory, anti-fibrotic and anti-oxidant properties, is 
approved worldwide for the treatment of IPF based on its ability to slow down functional decline and disease 
progression as shown in three phase III clinical trials11–13. Clinical trials however are usually performed in highly 
selected patient populations and in clinical settings that reflect only partially real-life clinical practice. Patients 
enrolled in clinical trials in fact tend to be younger, and have less severe disease and fewer comorbidities, with a 
shorter follow-up. Yet, reassuringly, outcomes of IPF patients treated with antifibrotic drugs (e.g., pirfenidone and 
nintedanib) in real-life appear to be comparable to those observed in clinical trials14.
In this longitudinal study, we aimed to assess long-term (24 months) response to pirfenidone treatment in a 
well-characterized cohort of patients with IPF in a real-life setting. The availability of data from patients followed 
up before the pirfenidone era gave us the unique opportunity to stratify our patient population in rapid and slow 
progressors based on their rate of FVC decline in the 12-month pretreatment period.
Results
A total of 56 patients were included in the study. Baseline patient demographics and clinical characteristics are 
summarized in Table 1. Most patients were males (78%) and ex-smokers (71%), with a median age at diagnosis 
of 67 years (range 37–78). Based on the annual FVC% pred. decline in the pretreatment period, 39 patients 
were classified as slow (FVC% pred. ≤10%) and 17 as rapid progressors (FVC% pred. >10%). Gender, age at 
diagnosis, smoking history and functional impairment (as assessed by FVC and DLCO) were similar in the two 
groups. Notably, a trend towards a higher FVC% pred. at diagnosis was seen in rapid progressors, consistent with 
previous publications from our group3. Pulmonary function data were available for all patients at the 12-month 
follow-up, and for most of them at 24 months (38 out of 56, 68%). Eighteen patients did not complete the study 
due to missed follow-up visits (n = 7), pirfenidone-related adverse effects (n = 2), lung transplantation (n = 3) 
or death (n = 6). Causes of death were related to chronic respiratory deterioration caused by IPF (n = 5) and left 
heart failure (n = 1). No acute exacerbations occurred in the entire study population; one possible explanation 
could be related to the selection bias as patients had to have a long (i.e. at least one year) follow-up without acute 
exacerbations before initiating pirfenidone treatment.
In the pretreatment period, three patients received low-dose steroids, and one N-acetyl cysteine. In the pre-
treatment period, the median rate of annual FVC decline was 231 ml (range −323 to 1140 ml) in the entire popu-
lation, 141 ml (range −323 to 375 ml) in slow progressors and 706 ml (range 242 to 1141 ml) in rapid progressors 
(Fig. 1A–C).
Disease progression in the entire IPF population during treatment. In the IPF population as a 
whole (n = 56), pirfenidone treatment reduced significantly the rate of annual FVC decline at all the time points 
examined compared to the pretreatment period. Specifically, the median rate of annual FVC decline changed 
from 231 ml/year (corresponding to 6% pred./year) in the pretreatment period to 49 ml/year at 6 months (T6) 
(0% pred., p = 0.003), and this reduction persisted at 12- (59 ml/year, 1% pred.), 18- (91 ml/year, 4% pred.) and 
24-month follow-up (87 ml/year, 2% pred.) (p value for trend from T6 to T24 n.s.) (Fig. 1A).
Similar results were observed when the patient populations from Padua, Modena, Foggia and Udine were 
analyzed separately (data not shown).
Effect of pirfenidone treatment in rapid and slow progressors. When rapid progressors (n = 17) and 
slow progressors (n = 39) were analyzed separately, the magnitude of pirfenidone effect on FVC decline varied 
greatly (Fig. 1B,C and Fig. 2A,B). Indeed, among rapid progressors the beneficial effect of pirfenidone on FVC 
decline was already evident at 6 months (T6), wherein the annual rate of FVC decline changed from 706 ml/year 
(20% pred.) in the pretreatment period to 36 ml/year (−5% pred., p = 0.002). The treatment effect was maintained 
at the 12- (106 ml/year, 1% pred.), 18- (176 ml/year, 7% pred.) and 24-month follow-up (162 ml/year, 5% pred.) (p 
value for trend from T6 to T24 n.s.) (Fig. 1B).
Entire population 
(n=56)
Slow progressors 
(n=39)
Rapid progressors 
(n=17) p value
Male - n (%) 44 (78%) 31 (79%) 13 (76%) 0.8
Age at diagnosis - years 67 (37–78) 67 (37–78) 67 (54–77) 0.8
Former smokers - n (%) 40 (71%) 28 (72%) 12 (71%) 0.9
Smoking history - Pack-Years 10 (0–60) 8.5 (0–60) 15 (0–60) 0.4
Radiologic diagnosis - n (%) 37 (66%) 24 (62%) 13 (76%) 0.3
FVC at diagnosis - L 2.66 (1.19–4.72) 2.72 (1.19–4.72) 2.66 (1.69–3.79) 0.5
FVC at diagnosis - %pred. 80 (35–116) 74 (35–116) 83 (61–105) 0.1
DLCO at diagnosis - %pred. 54 (28–114) 52 (28–114) 61 (48–75) 0.1
Transplanted patients - n 3 3 0 0.5
Deaths - n 6 5 1 0.4
Table 1. Demographics and clinical characteristics of the entire population (n = 56), slow progressors (n = 39) 
and rapid progressors (n = 17). Values are expressed as numbers and (%) or median and (ranges).
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Among slow progressors, the reduction of the annual FVC decline compared to the pretreatment period did 
not reach statistical significance at any of the time points examined, i.e. at 6 months (T6) (49 ml/year, 0% pred. vs. 
141 ml/year, 3% pred. pretreatment, p = 0.3) nor in any of the other follow-up time points (34 ml/year, 1% pred. 
at 12 months; 67 ml/year, 3% pred. at 18 months; 78 ml/year, 1% pred. at 24 months) (p value for trend from T6 
to T24 n.s.) (Fig. 1C).
Discussion
Pirfenidone is approved worldwide for the treatment of IPF based on its ability to slow down functional decline 
and disease progression11–13. The heterogeneous nature of IPF makes it difficult to foresee the clinical trajectory 
in individual patients, and this heterogeneity could conceivably also affect treatment response. In the present 
study, we report on the long-term (up to 24 months) efficacy of pirfenidone treatment in patients with IPF. These 
patients had been followed for a prolonged time before starting anti-fibrotic treatment, during which we had 
the opportunity to categorize them as rapid or slow progressors based on the rate of their FVC decline in the 
pretreatment period3. In our patient population as a whole, compared to the pretreatment period, pirfenidone 
reduced significantly the decline in FVC already at 6 months, and this reduction was maintained at the 12-, 
18- and 24-month follow-up. However, the effect of pirfenidone differed considerably between slow and rapid 
progressors, being significantly more pronounced in the latter group at all time points.
Before starting pirfenidone, our patients were followed-up for a median of 15 months, and this gave us the 
possibility to monitoring changes in FVC during an extended period of time, which, in turn, provided a reliable 
basis for the definition of rapid and slow disease progression. FVC is a valid and reproducible measure of dis-
ease progression in patients with IPF1,7,15. IPF patients who experience a decrease of >10% in FVC% pred. over 
a 12-month period (rapid progressors) display a significantly lower 5-year survival than patients whose FVC% 
pred. declines ≤10% (slow progressors)8. Given the differences in the described rates of decay in IPF, it is conceiv-
able that treatment response might also differ in subjects with rapid and slow decline. Accordingly, it is important 
to prospectively investigate this possibility.
When we considered our whole population together, the annual rate of FVC decline in the pretreatment 
period was 231 ml/year (6% pred.) similar to what has been reported in the placebo arms of other treatment 
trials13. With pirfenidone, the rate of FVC decline was variably but significantly reduced already after 6 months 
of treatment, an improvement that was maintained during the entire 24-month study duration. Overall, after 
one year of pirfenidone treatment, 7 (12%) patients experienced a FVC decline >10% compared with 17 patients 
(30%) in the pretreatment period (OR 3.0, p = 0.02), corresponding to a relative reduction of 59%, while the 
absolute fall of FVC decreased from a pretreatment value of 231 ml/year to 59 ml/year (p < 0.05), consistent with 
a previous study in Japanese patients16. Our data provide, we believe, a reliable picture of the effect of pirfenidone 
treatment on the rate of FVC change between the pretreatment and follow-up period, since each patient served as 
its own control, which clearly strengthens our findings.
Figure 1. Panel (A) Annual FVC decline in the entire population (n = 56) before and after pirfenidone 
treatment at 6 (T0-T6), 12 (T0-T12), 18 (T0-T18) and 24 (T0-T24) months. Overall comparison between 
all time points was performed using the repeated measurements analysis of variance (ANOVA) (p = 0.03). 
Pirfenidone reduced significantly the annual decline in FVC already at 6 months (paired t-test, p = 0.003) and 
this reduction was maintained at 12-, 18- and 24-month follow-up (repeated measures analysis of variance 
at all time points, p = n.s.). Panel (B) Annual FVC decline in the rapid progressors (n = 17) before and after 
pirfenidone treatment at 6 (T0-T6), 12 (T0-T12), 18 (T0-T18) and 24 (T0-T24) months. Overall comparison 
between all time points was performed using the repeated measurements analysis of variance (ANOVA) 
(p < 0.001). Pirfenidone reduced significantly the annual decline in FVC already at 6 months (paired t-test, 
p < 0.01) and this reduction was maintained at 12-, 18- and 24-month follow-up (repeated measures analysis 
of variance at all time points, p = n.s.). Panel (C) Annual FVC decline in the slow progressors (n = 39) before 
and after pirfenidone treatment at 6 (T0-T6), 12 (T0-T12), 18 (T0-T18) and 24 (T0-T24) months. Overall 
comparison between all time points was performed using the repeated measurements analysis of variance 
(ANOVA) (p = 0.1). Pirfenidone did not significantly reduce the annual decline in FVC at any of the time points 
examined (paired t-test, p = n.s.; repeated measures analysis of variance at all time points, p = n.s.). Negative 
values mean improvement of FVC. Horizontal bars represent median values, bottom and top of each box plot 
represents 25th and 75th percentiles, brackets 10th and 90th percentiles, while circles represent outliers.  
*p value < 0.01, n.s. non significant.
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The effect of pirfenidone differed significantly between slow and rapid progressors. Among rapid progressors, 
the median decline of FVC prior to treatment was 706 ml/year, which was reduced to 36 ml/year after 6 months 
of treatment. Overall, the pirfenidone effect was significantly maintained throughout the two-year study period. 
Pirfenidone was also beneficial for patients with slow pretreatment decline since, although the rate of FVC decline 
did not change significantly, it seemed to stabilise the disease.
Our results are in line with those of previous retrospective analyses of lung function changes in patients with 
mild to moderate IPF treated with pirfenidone17,18. These studies showed that patients with progressive disease 
(e.g., FVC% pred. decline > 10% per year) may benefit substantially from pirfenidone treatment, which may even 
result in improvement of FVC, as shown by Loeh et al.18, while patients with slowly progressive disease tend to 
experience disease stability under treatment. The assessment of disease progression and treatment response in 
patients with IPF is complicated by its variable clinical course2. In a recent post-hoc analysis of patients from the 
placebo arms of the CAPACITY and ASCEND trials19, Nathan and colleagues observed a weak negative correla-
tion between changes in FVC% pred. during two consecutives 6-month intervals, that the authors interpreted as 
a reflection of the variability in both the magnitude and direction of change. An important source of variability 
in that study could have been the combined analysis of slow and rapid progressors together, particularly since the 
follow-up period was relatively short (i.e., 6 months). In our study, the median pretreatment observation period 
was 15 months, which minimizes the possibility that the observed rate of disease progression was confounded by 
the inherent intra-individual variability in longitudinal change in FVC.
A recent multicentre study20 confirmed the efficacy of pirfenidone in slowing down disease progression in 
patients with IPF, but suggested that the beneficial effect would be more pronounced in patients with more severe 
disease. This was not the case in our study, since at diagnosis the severity of the disease in our population was 
similar in rapid and slow progressors.
The mechanisms through which rapid progressors display a particularly favorable response to pirfenidone 
treatment is not known but may be related to differences in the described lung pathology in the slow and rapid 
IPF groups3. Possibly, extracellular matrix deposition and removal may be much more rapid, thus amenable 
to anti-fibrotic therapy, in the rapid progressive than in relatively stable IPF18,21. Recently, we have shown that 
explanted lungs from IPF subjects had similar degree of fibrosis deposition and numbers of fibroblast foci in 
slow and rapid progressors3. This finding might be due to a more rapid fibrous tissue deposition in the rapid 
decliner perhaps more amenable to lysis and degradation by pirfenidone. Alternatively, pirfenidone might 
play a prominent immunosuppressive and antioxidant role, with the antioxidant properties contributing to its 
anti-inflammatory effects, which in turn may account, at least in part, for pirfenidone’s antifibrotic effects22,23. We 
have reported that rapidly progressive IPF, compared to slow or stable disease, is characterized by a significantly 
higher innate and adaptive inflammation in the lung parenchyma. This might contribute significantly to the accel-
erated decline of this group of patients and would also make the disease more responsive to a compound with 
anti-inflammatory and anti-fibrotic properties3,24.
The presence of an exuberant immune inflammatory infiltrate, found predominantly in the rapid progres-
sors, is consistent with the gene expression profile reported by Boon and colleagues10, who indeed described the 
Figure 2. Panel (A) Individual FVC trajectories in rapid progressors from pretreatment period through 2-year 
follow-up. Overall comparison between all time points was performed using the repeated measurements 
analysis of variance (ANOVA) (p < 0.001). In the pretreatment period, the FVC trajectory of the rapid 
progressors is depicted by a line with a steep slope. Whereas, after the institution of pirfenidone (vertical 
dotted line), FVC trajectory is depicted by a line with a significantly flatter slope compared to the pretreatment 
period (paired t-test, p < 0.01). The FVC values during treatment were stable in the 2-year follow-up (repeated 
measures analysis of variance at 1-year and 2-year time points, p = n.s.). (B) Individual FVC trajectories in slow 
progressors from pretreatment period through 2-year follow-up. Overall comparison between all time points 
was performed using the repeated measurements analysis of variance (ANOVA) (p = n.s.). In the pretreatment 
period, the FVC trajectory of the slow progressors is depicted by a line with a flat slope. After the institution of 
pirfenidone (vertical dotted line), FVC trajectory is depicted by a line with a slope as flat as the pretreatment 
period (paired t-test, n.s.). The FVC values during treatment were stable in the 2-year follow-up (repeated 
measures analysis of variance at 1-year and 2-year time points, p = n.s.). FVC (on the y axis) is expressed as 
litres. *p value < 0.01, n.s. non significant.
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activation of important pro-inflammatory pathways that may potentially play a role in the immune activation 
and disease progression in rapid decliners. In line with these reports it is also the presence of B cell aggregates25 
and highly differentiated circulating B cells in patients with IPF26, findings usually observed in autoimmune 
syndromes. Our findings of an increased number of B lymphocytes and T lymphocytes in the lungs of rapid 
progressors3 are also in keeping with previous observations showing that lymphocyte density in IPF lung is asso-
ciated with FVC decline and poor survival27. Although speculative and based on pathological description of the 
disease, we believe these possibilities deserve some attention since they might explain, at least in part, the different 
response to pirfenidone treatment.
The rate of discontinuation of pirfenidone due to adverse events observed in our patient population (3.5%) 
was lower than that observed in the CAPACITY12 (14.8%) and ASCEND13 (14.4%) trials, confirming the safety 
and tolerability of the drug in clinical practice.
Our long-term prospective study, even if relatively small, provides further evidence of the efficacy of pirfeni-
done in patients with IPF up to 24 months of treatment and shows that response to therapy is influenced by the 
rate of decline, slow or rapid, in the pretreatment period. Strengths of our study include the careful patient char-
acterization and the availability of long-term pre- and post-treatment data. Owing to the progressive nature of the 
disease and the availability worldwide of two efficacious anti-fibrotic drugs (pirfenidone and nintedanib), studies 
on IPF patients off-treatment will become progressively less common, if at all possible (and ethical). This makes 
our data regarding the pretreatment period particularly relevant.
Our study has some limitations. Firstly, the size of our study population is relatively small, and it decreased 
over time; indeed, follow-up data at 24 months were available for 38/56 patients only (68%). Secondly, we limited 
our analysis to change in FVC. Despite uncertainties about its clinical meaningfulness and handling of missing 
data, FVC is widely accepted as surrogate of treatment efficacy in IPF both in clinical trials and at regulatory 
level8,15,28,29. Contrary to clinical trials however, we decided neither to impute missing values for patients who 
stopped pirfenidone treatment at some point during the observation period nor to set FVC as 0 for patients who 
died or underwent lung transplantation, as previously done13.
Conclusions
The study confirms that pirfenidone treatment reduces significantly the rate of FVC decline in patients with IPF, 
an effect that is significantly more pronounced in patients with rapidly progressive disease. Additional studies are 
required to identify more precisely the underlying differences in disease behavior and treatment response of the 
slow and rapid decliners in IPF. This will greatly benefit clinical research and daily clinical practice alike.
Methods
Patients and study design. Informed consent was obtained for all study participants. This was a prospec-
tive, longitudinal, multicenter study, in which we analyzed a unique and well-characterized cohort of patients 
with IPF, with a long clinical and functional follow-up before and after the initiation of pirfenidone treatment. 
Fifty-six patients were selected from four Italian Interstitial Lung Disease (ILD) centers (e.g., University Hospital 
of Padua, n = 27; University Hospital of Foggia, n = 14; University Hospital of Modena, n = 10; and General 
Hospital of Udine, n = 5). For all patients, the diagnosis of IPF was made in accordance with current guidelines1.
The peculiarity of this study was to include only patients for whom lung function data were available for at 
least one year before (pretreatment period) starting pirfenidone treatment. Based on their annual rate of decline in 
FVC% pred. in the pretreatment period, patients were classified as either “rapid” (decline in FVC% pred. >10%) 
or “slow” (decline in FVC% pred. ≤10%) progressors. They were then followed-up during pirfenidone treatment 
every 6 months up to 24 months (follow-up period). At the 12-month follow-up, functional data were available 
for the entire patient population, whereas at 24 months functional data were available for 38/56 (68%) patients.
Negative values of annual FVC decline during the follow-up indicated amelioration. The study was performed 
in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the University 
Hospital of Padua (4280/AO/17).
Additional important clinical and functional parameters, including symptoms, diffusing capacity of the lung 
for carbon monoxide (DLCO) and 6-minute walking test, were also collected but the amount of missing data did 
not allow for a meaningful statistical analysis to be performed.
Statistical analysis. Categorical variables were described as absolute (n) and relative values (%) and contin-
uous variable were described as median and range. To compare demographic data and baseline clinical charac-
teristics between rapid and slow progressors Chi-square test for categorical variables and Mann-Whitney test for 
the continuous variables were used.
In the entire population, as well as in the rapid and slow progressor subgroups, we performed the repeated 
measurements analysis of variance (ANOVA) at all time points to evaluate the difference in FVC decline between 
pretreatment and the follow-up period. To evaluate the difference between the pretreatment FVC decline and the 
first time point available (6 months) in the follow-up period in the entire population, in the rapid progressors and 
in the slow progressors we performed a paired t-test analysis. Finally, in order to evaluate whether this potential 
difference was maintained in the follow-up period (6, 12, 18 and 24 months), we performed the repeated meas-
urements analysis of variance (ANOVA) between these time points in the entire population, and in the rapid and 
slow progressor subgroups.
All data were analysed using SPSS Software version 22.0 (IBM USA). p-values < 0.05 were considered statis-
tically significant.
Data availability. All data generated or analyzed during this study are included in this published article.
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